natgillin/translations-raw huggingface dataset:
Side effects of unknown frequency (frequency cannot be estimated from the available data) Inflammation of the salivary gland, skin and lip cancer (Non-melanoma skin cancer), decreases in the number (or even lack) of cells in the blood, including low red and white blood cell count, serious allergic reactions (e.g. hypersensitivity, anaphylactic reaction), decreased or loss of appetite, restlessness, light-headedness, blurred or yellowing of vision, decrease in vision and eye pain (possible signs of acute myopia or acute-angle closure glaucoma), inflammation of blood vessels (vasculitis necrotising), inflamed pancreas, upset stomach, yellowing of the skin or eyes (jaundice), lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body's immune system attacks the body); skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, rash, redness of the skin, blistering of the lips, eyes or mouth, skin peeling , fever (possible signs of erythema multiforme), weakness, kidney inflammation or impaired kidney function, glucose in the urine (glycosuria), fever, impaired electrolyte balance, high blood cholesterol levels, decreased blood volume, increased blood levels of glucose, difficulties in controlling blood/ urine levels of glucose in patients with a diagnosis of diabetes mellitus, or fat in the blood.
Upala žlijezda slinovnica, rak kože i usana (nemelanomski rak kože), smanjenje broja (ili čak nedostatak) stanica u krvi, uključujući niske vrijednosti crvenih i bijelih krvnih stanica, ozbiljne alergijske reakcije (npr. preosjetljivost, anfilaktička reakcija), smanjen ili gubitak apetita, nemir, ošamućenost, zamućeni vid ili žutilo pred očima, slabljenje vida i bol u oku (mogući znakovi akutne kratkovidnosti ili akutnog glaukoma zatvorenog kuta), upala krvnih žila (nekrotizirajući vaskulitis), upala gušterače (pankreatitis), nadražen želudac, žutilo kože ili bjeloočnica (žutica), sindrom sličan lupusu (stanje koje oponaša bolest koja se naziva sistemski lupus eritematozus pri kojem imunološki sustav tijela napada tijelo), poremećaji kože kao što je upala krvnih žila kože, povećana osjetljivost na sunčevu svjetlost, osip, crvenilo kože, mjehurići na usnicama, očima ili u ustima, ljuštenje kože, vrućica (mogući znakovi multiformnog eritema), slabost, upala bubrega ili oštećenje bubrežne funkcije, glukoza u urinu (glikozurija), vrućica, poremećena ravnoteža elektrolita, visoke vrijednosti kolesterola u krvi, smanjeni volumen krvi, povišene vrijednosti glukoze u krvi, poteškoće s kontrolom razine glukoze u krvi/urinu u bolesnika s dijagnozom šećerne bolesti, ili masnoća u krvi.
- Heart trouble.
- poteškoće sa srcem. - šećerna bolest.
There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Dvostruka blokada sustava renin-angiotenzin-aldosteron (RAAS) Postoje dokazi da istodobna primjena ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena povećava rizik od hipotenzije, hiperkalemije i smanjene bubrežne funkcije (uključujući akutno zatajenje bubrega).
Nervous system disorders Rare:
Poremećaji živčanog sustava Često:
14 tablets 28 tablets 30 tablets 56 tablets 84 tablets 90 tablets 98 tablets
14 tableta 28 tableta 30 tableta 56 tableta 84 tableta 90 tableta 98 tableta
Thiazide diuretic associated azotaemia may occur in patients with impaired renal function.
Kod bolesnika s oštećenom bubrežnom funkcijom može doći do pojave azotemije povezane s tiazidskim diuretikom.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je bilo ispitivanje osmišljeno za testiranje koristi dodavanja aliskirena standardnoj terapiji s
Renal impairment and kidney transplantation
Poremećaji bubrega i mokraćnog sustava
The overall incidence and pattern of adverse reactions reported with telmisartan/hydrochlorothiazide 80 mg/25 mg was comparable with telmisartan/hydrochlorothiazide 80 mg/12.5 mg. A doserelationship of adverse reaction was not established and they showed no correlation with gender, age or race of the patients.
Ukupna incidencija i obrazac nuspojava prijavljenih uz telmisartan/hidroklportiazid 80 mg/25 mg usporedivi su s onima telmisartana/hidroklorotiazida 80 mg/12,5 mg.
Actelsar HCT 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
Actelsar HCT 80 mg/25 mg tablete telmisartan/hidroklorotiazid
Stomach discomfort Skin and subcutaneous tissue disorders Rare:
Poremećaji mišićno-koštanog sustava i vezivnog tkiva Rijetko:
28 tablets 56 tablets 84 tablets 90 tablets 98 tablets
28 tableta 56 tableta 84 tableta 90 tableta 98 tableta
Package leaflet: Information for the user Actelsar HCT 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
Uputa o lijeku: Informacije za korisnika Actelsar HCT 80 mg/25 mg tablete telmisartan/hidroklorotiazid
Aplastic anaemia, haemolytic anaemia, bone marrow failure, leukopenia, neutropenia, agranulocytosis,
Aplastična anemija, hemolitička anemija, zatajenje koštane srži,
Package leaflet: Information for the user Actelsar HCT 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Uputa o lijeku: Informacije za korisnika Actelsar HCT 40 mg/12,5 mg tablete telmisartan/hidroklorotiazid
14 tablets 28 tablets 56 tablets 84 tablets 90 tablets 98 tablets
14 tableta 28 tableta 56 tableta 84 tableta 90 tableta 98 tableta
Antidiabetic medicinal products (oral agents and insulin)
Nesteroidni protuupalni lijekovi (NSAIL-i)
Actelsar HCT 80 mg/12.5 mg tablets White or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked with “TH 12.5” on both sides.
Bijele ili gotovo bijele tablete u obliku kapsula, dimenzija 9,0 x 17,0 mm, s obje strane označene oznakom „TH 12.5“.
Reykjavíkurvegur 78, 220 Hafnarfjörður, Iceland
Actavis hf. Reykjavíkurvegur 78, 220 Hafnarfjörður, Island
Package leaflet: Information for the user Actelsar HCT 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Uputa o lijeku: Informacije za korisnika Actelsar HCT 80 mg/12,5 mg tablete telmisartan/hidroklorotiazid
Actelsar HCT 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Actelsar HCT 80 mg/12,5 mg tablete telmisartan/hidroklorotiazid
Diabetes mellitus inadequate control Metabolism and nutrition disorders Common:
Poremećaji metabolizma i prehrane Često:
How to store Actelsar HCT
Moguće nuspojave Kako čuvati Actelsar HCT
Actelsar HCT 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Actelsar HCT 40 mg/12,5 mg tablete telmisartan/hidroklorotiazid
- Actelsar HCT 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 40 mg - Actelsar HCT 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 80 mg
Actelsar HCT 40 mg/12,5 mg se primjenjuje jedanput dnevno kod bolesnika čiji se krvni tlak adekvatno ne kontrolira telmisartanom 40 mg.
- Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
- stenoza bubrežne arterije (sužavanje krvnih žila koje vode u jedan ili oba bubrega). - bolest jetre.
Al/Al blister: 14, 28, 30, 56, 84, 90 and 98 tablets Al/PVC/PVDC blister: 28, 56, 84, 90 and 98 tablets Tablet container: 30, 90 and 250 tablets
Al/Al blister: 14, 28, 30, 56, 84, 90 i 98 tableta Al/PVC/PVDC blister: 28, 56, 84, 90 i 98 tableta Spremnik s tabletama: 30, 90 i 250 tableta
Al/Al blister packs: 14, 30, 28, 56, 84, 90 and 98 tablets Al/PVC/PVDC blister packs: 14, 28, 56, 84, 90 and 98 tablets Tablet containers: 30, 90 and 250 tablets
Al/Al blister pakiranja: 14, 28, 30, 56, 84, 90 i 98 tableta Al/PVC/PVDC blister pakiranja: 14, 28, 56, 84, 90 i 98 tableta Spremnici s tabletama: 30, 90 i 250 tableta
Al/Al blister packs: 14, 28, 30, 56, 84, 90 and 98 tablets Al/PVC/PVDC blister packs: 28, 56, 84, 90 and 98 tablets Tablet containers: 30, 90 and 250 tablets
Al/Al blister pakiranja: 14, 28, 30, 56, 84, 90 i 98 tableta Al/PVC/PVDC blister pakiranja: 28, 56, 84, 90 i 98 tableta Spremnici s tabletama: 30, 90 i 250 tableta
Eczema, drug eruption, toxic skin eruption Musculoskeletal, connective tissue and bone disorders Rare:
hiperhidroza, urtikarija Poremećaji mišićno-koštanog sustava i vezivnog tkiva
Talk to your doctor before taking Actelsar HCT, if you are taking: - any of the following medicines used to treat high blood pressure: an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću.
How to store Actelsar HCT Contents of the pack and other information
Sadržaj pakiranja i druge informacije
Actelsar HCT 40 mg/12.5 mg tablets are white or almost white, 6.55 x 13.6 mm oval-shaped and biconvex tablets marked with “TH” on one side.
Actelsar HCT 40 mg/12,5 mg tablete su bijele ili gotovo bijele ovalne bikonveksne tablete, dimenzija
Nervous system disorder Rare:
Poremećaji probavnog sustava Manje često:
This can lead to permanent vision impairment, if not treated.
Ako se ne liječe, mogu dovesti do trajnog oštećenja vida.
Actelsar HCT 80 mg/12.5 mg tablets are white or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked with “TH 12.5” on both sides.
Actelsar HCT 80 mg/12,5 mg tablete su bijele ili gotovo bijele tablete u obliku kapsula, dimenzija
Inflammation of the lungs (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body's immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses, feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood.
otežano disanje, bol u trbuhu, zatvor, nadutost (probavne tegobe), osjećaj mučnine (povraćanje), upala želuca (gastritis), abnormalna jetrena funkcija (japanska populacija ima veće izglede za ovu nuspojavu), crvenilo kože (eritem), alergijske reakcije kao što su svrbež ili osip, pojačano znojenje,
- Medicines associated with low blood potassium (hypokalaemia) such as other diuretics, (“water tablets”), laxatives (e.g. castor oil), corticosteroids (e.g. prednisone), ACTH (a hormone), amphotericin (an antifungal medicine), carbenoxolone (used to treat mouth ulcers), penicillin G sodium (an antibiotic), and salicylic acid and derivatives.
- lijekovi koji su povezani s niskim vrijednostima kalija u krvi (hipokalemija) kao što su drugi diuretici („tablete za izmokravanje”), laksativi (npr. ricinusovo ulje), kortikosteroidi (npr.
Blood and lymphatic system disorders Rare:
Poremećaji krvi i limfnog sustava
The virus has first been inactivated so that it does not cause any disease.
Virus je najprije inaktiviran tako da ne može prouzrokovati nikakvu bolest.
However, it may be appropriate to give the vaccine to these patients during a pandemic, as long as facilities for resuscitation are available.
Međutim, bilo bi preporučljivo dati cjepivo tim bolesnicima tijekom pandemije, pod uvjetom da su dostupne prostorije za oživljavanje.
Further information on Aflunov can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/aflunov.
Više informacija o cjepivu Aflunov dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/aflunov.
What measures are being taken to ensure the safe and effective use of Aflunov?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena cjepiva Aflunov?
This vaccine contains some parts of the H5N1 virus.
Ovo cjepivo sadrži neke dijelove virusa H5N1.
The vaccine contains an ‘adjuvant' (a compound containing oil) to enhance the immune response.
Cjepivo sadrži „adjuvans” (spoj koji sadrži ulje) radi poboljšanja imunosnog odgovora.
Aflunov can only be obtained with a prescription and should be used according to official recommendations
Aflunov se izdaje samo na recept te se treba primjenjivati u skladu sa službenim preporukama.
What is Aflunov and what is it used for?
Što je Aflunov i za što se koristi?
When the person comes into contact with the virus, these antibodies, together with other components of the immune system, will be able to kill the virus and help protect against the disease.
Kada osoba dođe u kontakt s virusom, ta će protutijela zajedno s drugim dijelovima imunosnog sustava moći uništiti virus i pomoći pri zaštiti od bolesti.
Aflunov should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, including those found at trace (very low) levels (egg or chicken protein, ovalbumin [a protein in egg white], kanamycin or neomycin sulphate [antibiotics], barium sulphate, formaldehyde and cetyltrimethylammonium bromide).
Cjepivo Aflunov ne smije se davati bolesnicima koji su imali anafilaktičku reakciju (tešku alergijsku reakciju) na bilo koju komponentu cjepiva, uključujući i one koje su prisutne u tragovima, tj. u vrlo niskim razinama (jaje ili pileći proteini, ovalbumin [ protein bjelanjka], kanamicin ili neomicinsulfat [antibiotici], barijev sulfat, formaldehid i cetiltrimetilamonijev bromid).
The vaccine is given by injection into the shoulder muscle in two single doses, at least three weeks apart.
Cjepivo se daje injekcijom u rameni mišić u dvije pojedinačne doze u razmaku od najmanje tri tjedna.
Aflunov received a marketing authorisation valid throughout the EU on 29 November 2010.
Cjepivo Aflunov dobilo je odobrenje za stavljanje u promet koje je na snazi u EU-u od 29. studenoga
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aflunov have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene cjepiva Aflunov nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
Aflunov is a type of vaccine to be given before or during a flu pandemic to protect against a new strain of flu.
Aflunov je vrsta cjepiva koja se daje prije ili za vrijeme pandemije gripe radi zaštite od novoga soja gripe.
Aflunov contains parts of influenza (flu) viruses that have been inactivated.
Alfunov sadrži određene dijelove virusa influence (gripe) koji su inaktivirani.
The European Medicines Agency therefore decided that Aflunov's benefits are greater than its risks and it can be authorised for use in the EU.
Europska agencija za lijekove stoga je zaključila da koristi od cjepiva Aflunov nadmašuju s njim povezane rizike te da cjepivo može biti odobreno za primjenu u EU-u.
Side effects reported with Aflunov are carefully evaluated and any necessary action taken to protect patients.
Nuspojave prijavljene za cjepivo Aflunov pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
The studies looked at the ability of the vaccine to trigger the production of antibodies (‘immunogenicity') against the flu virus.
Ispitivanja su bila usmjerena na sposobnost cjepiva da pokrene proizvodnju protutijela („imunogenost”) protiv virusa gripe.
When a person is given the vaccine, the immune system recognises the virus parts in the vaccine as ‘foreign' and makes antibodies against them.
Kada osoba primi cjepivo, imunosni sustav prepoznaje dijelove virusa u cjepivu kao „strana tijela” i proizvodi protutijela na njih.
An overview of Aflunov and why it is authorised in the EU
Pregled informacija o cjepivu Aflunov i zašto je odobreno u EU-u
In the event of an officially declared pandemic caused by the H5N1 strain of the influenza A, people who have already been vaccinated with Aflunov (with one or two doses) may be given only one more dose, instead of the two doses recommended for unvaccinated people.
U slučaju službeno proglašene pandemije koju je prouzrokovao soj virusa H5N1 influence tipa A, osobe koje su već cijepljene cjepivom Aflunov (s jednom ili dvije doze) mogu primiti još samo jednu dozu cjepiva umjesto preporučene dvije za osobe koje nisu cijepljene.
In one study involving 3,372 people, subjects were given either a seasonal flu vaccine followed by two doses of Aflunov three weeks apart, or placebo (a dummy vaccine) followed by two doses of an adjuvanted seasonal vaccine three weeks apart.
U jednom ispitivanju koje je obuhvaćalo 3372 osobe, ispitanici su primili sezonsko cjepivo protiv gripe i nakon tri tjedna dvije doze cjepiva Aflunov ili su primili placebo (prividno cjepivo) i nakon toga dvije doze adjuvantiranog sezonskog cjepiva u razmaku od tri tjedna.
As for all medicines, data on the use of Aflunov are continuously monitored.
Kao i za sve lijekove, podatci o primjeni cjepiva Aflunov kontinuirano se prate.
Other information about Aflunov
Ostale informacije o cjepivu Aflunov
In the first study, 21 days after the second injection, around 90% of people aged below 60 years and around 80% of those aged above 60 years had levels of antibodies that would protect them against H5N1.
U prvom ispitivanju otprilike 90 % osoba mlađih od 60 godina i otprilike 80 % onih starijih od 60 godina imalo je razine protutijela koje bi ih zaštitile od virusa H5N1.
The most common side effects with Aflunov (which may affect more than 1 patient in 10) are headache, myalgia (muscle pain), reactions at the site of injection (swelling, pain, induration and redness) and fatigue (tiredness).
Najčešće nuspojave cjepiva Aflunov (koje se mogu javiti u više od 1 na 10 bolesnika) su glavobolja, mijalgija (bol u mišićima), reakcije na mjestu injekcije (oticanje, bol, otvrdnuće i crvenilo) i umor.
Why is Aflunov authorised in the EU?
Zašto je cjepivo Aflunov odobreno u EU-u?
Aflunov contains a flu strain called A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1).
Aflunov sadrži soj gripe zvan A/turkey/Turkey/1/2005 (H5N1)-sličan soj (NIBRG-23) (klada 2.2.1).
In the second study involving 240 people, subjects were given Aflunov using different vaccination schedules.
U drugome ispitivanju koje je obuhvaćalo 240 osoba, ispitanici su primili cjepivo Aflunov pri čemu su se koristili različiti režimi cijepljenja.
Aflunov has been shown to produce sufficient antibodies to stimulate an immune response and protect against H5N1.
Dokazano je da Aflunov proizvodi dovoljno protutijela za poboljšanje imunosnog odgovora i zaštitu od virusa H5N1.
What are the risks associated with Aflunov?
Koji su rizici povezani s cjepivom Aflunov?
At the time of the initial marketing authorisation, two main studies using a strain called A/Vietnam/1194/2004 (H5N1)-like strain (NIBRG-14) provided data on vaccination with Aflunov in healthy adults aged below and above 60 years.
U vrijeme izdavanja prvotnog odobrenja za stavljanje lijeka u promet, u okviru dvaju glavnih ispitivanja u kojima se koristio soj zvan A/Vietnam/1194/2004 (H5N1) - sličan soj (NIBRG-14) dostavljeni su podatci o cijepljenju zdravih odraslih osoba mlađih i starijih od 60 godina cjepivom Aflunov.
This study established that Aflunov should be given as two doses at least three weeks apart.
Ispitivanjem je utvrđeno da se cjepivo Aflunov treba davati u dvije doze s razmakom od najmanje tri tjedna.
It was noted that it is likely that a H5N1 strain of influenza will cause a pandemic in the future and Aflunov was shown to produce sufficient antibodies to stimulate an immune response and protect against H5N1.
Navedeno je da će u budućnosti soj virusa influence H5N1 vjerojatno prouzrokovati pandemiju, a utvrđeno je da cjepivo Aflunov proizvodi dovoljno protutijela za stimulaciju imunosnog odgovora i zaštitu protiv H5N1.
Aflunov is a vaccine used in adults to protect against flu caused by the H5N1 (‘bird flu') strain of the influenza A virus.
Alfunov je cjepivo koje se koristi u odraslih osoba radi zaštite od gripe uzrokovane sojem virusa H5N1 („ptičja gripa”) influence tipa A.
A third study, using a vaccine with strain A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23), was carried out in 343 adults aged below and above 60 years.
Treće je ispitivanje, u kojem je korišteno cjepivo sa sojem A/turkey/Turkey/1/2005 (H5N1)- sličan soj (NIBRG-23), provedeno na 343 odrasle osobe mlađe i starije od 60 godina.
The study showed that 21 days after the second injection, around 70% of adults below 60 years and around 64% of adults above 60 years produced an acceptable antibody response.
Ispitivanjem je utvrđeno da je oko 70 % osoba mlađih od 60 godina i otprilike 64 % osoba starijih od 60 godina proizvelo prihvatljiv odgovor protutijela 21 dan nakon druge injekcije.
How does Aflunov work?
Kako djeluje Aflunov?
What benefits of Aflunov have been shown in studies?
Koje su koristi od cjepiva Aflunov utvrđene u ispitivanjima?
For the full list of side effects of Aflunov, see the package leaflet.
Potpuni popis zabilježenih nuspojava povezanih s cjepivom Aflunov potražite u uputi o lijeku.
How is Aflunov used?
Kako se Aflunov primjenjuje?
A flu pandemic happens when a new strain of flu virus appears that can spread easily from person to person because people do not have immunity (protection) against it. Health experts are concerned that a future flu pandemic could be caused by the H5N1 strain of the virus, an infection that can spread from birds to humans (a ‘zoonotic' infection).
Stručnjaci u području medicine zabrinuti su da bi buduću pandemiju gripe mogao prouzrokovati soj virusa H5N1, infekcija koja se može proširiti s ptica na ljude (zoonozna infekcija).
- had a serious heart problem during the past 6 months
- ako ste imali ozbiljnih srčanih problema u posljednjih 6 mjeseci
Always take this medicine exactly as your doctor has told you.
Uvijek uzmite ovaj lijek točno onako kako Vam je rekaoVaš liječnik.
Do not use this medicine if you notice any change in the appearance of the capsules.
Ovaj lijek se ne smije upotrijebiti ako primijetite bilo kakve promjene u izgledu kapsula.
Poligono Industrial Malpica 50016 Zaragoza Spain
Poligono Industrial Malpica 50016 Zaragoza Španjolska
Date of first authorisation: 31 March 2009 Date of latest renewal: 16 January 2014
Datum zadnje obnove: 16. siječnja 2014
Do not take a double dose to make up for a forgotten dose
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
Do not take Ribavirin Teva if any of the following apply to you or the child you are caring for.
Nemojte uzimati Ribavirin Teva ako se bilo što od navedenog odnosi na Vas ili dijete o kojem skrbite.
- Depending upon the results of these tests, your doctor may change/adjust the number of capsules you or the child you are caring for take, prescribe a different pack size of this medicine, and/or change the length of time to take this treatment.
- Ovisno o rezultatima tih pretraga, liječnik može promijeniti/prilagoditi broj kapsula koje uzimate Vi ili dijete o kojem skrbite, propisati drugu veličinu pakiranja ovog lijeka i/ili promijeniti duljinu trajanja liječenja.
Ninety four of 107 children enrolled in the 5 year long-term follow up trial.
Devedeset i četiri od 107 djece uključeno je u 5-godišnje dugotrajno ispitivanje praćenja.
Elderly (≥ 65 years of age)
Stariji (≥ 65 godina)
This should be discussed with your doctor (see “Do not take Ribavirin Teva”).
O tome morate razgovarati sa svojim liječnikom (vidjeti dio "Nemojte uzimati Ribavirin Teva ").
Girl or woman of childbearing age:
• Djevojke ili žene u reproduktivnoj dobi: